/ /

  • linkedin
  • Increase Font
  • Sharebar

    Examining 1-year LUCAS Study results for AMD treatments


    Oslo, Norway—The 1-year results of the inject-and-extend Lucentis Compared to Avastin Study (Lucas) for exudative age-related macular degeneration (AMD) indicated that the two drugs have equivalent effectiveness, said Karina Berg, MD.

    “This is the first study of the drugs using an inject-and-extend protocol,” said Dr. Berg, Department of Ophthalmology, Oslo University Hospital, Oslo.

    The prospective, randomized, double-blind, multicenter, non-inferiority trial included 432 patients with active choroidal neovascularization and edema involving the fovea. The best-corrected visual acuity (VA) levels ranged from 20/25 to 20/320.

    The patients were randomly assigned to either ranibizumab (Lucentis, Genentech) or bevacizumab (Avastin, Genentech). Both groups were well matched at baseline for sex, age, VA, and retinal thickness.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results